Biochemical and Molecular Genetic Characterization of G6PD Deficiency in Newborn, Benin

AKPOVI D. Casimir^1, , FIOGBE E.M. Salomon¹, Julien G.A. SEGBO¹, Paulin SEDAH², Fifamè E.E. KOUGNIMON¹, Gratien G. SAGBO³ and Clément AGBANGLA²

¹Research Unit of Non Communicable Diseases and Cancer, Research Laboratory in Applied Biology, “Ecole Polytechnique d’Abomey-Calavi”, University of Abomey-Calavi, Benin

²Laboratory of Molecular Genetics and Genome Analyzes, Faculty of Sciences and Technics, University of Abomey-Calavi, Benin

³Medical Genetics and Neonatology, “Centre National Hospitalier et Universitaire H.K. Maga”, Cotonou, Benin

Cite this paper:
AKPOVI D. Casimir, FIOGBE E.M. Salomon, Julien G.A. SEGBO, Paulin SEDAH, Fifamè E.E. KOUGNIMON, Gratien G. SAGBO and Clément AGBANGLA. Biochemical and Molecular Genetic Characterization of G6PD Deficiency in Newborn, Benin. American Journal of Biomedical Research. 2019; 7(2):32-37. doi: 10.12691/ajbr-7-2-2

Abstract

Background: In Benin, the diagnosis of G6PD deficiency is based on the biochemical test performed by the quantitative spectrophotometry assay of the enzymatic activity. We used the results of the molecular gene test to verify the reliability of the biochemical diagnostic test. The distribution of genes polymorphism associated with the G6PD deficiency in neonates is also determined throughout the country. Material and Methods: This is a cross-sectional descriptive study carried on with 178 neonates aged ≤7 days. Blood samples were screened for quantitative G6PD enzymatic activity using Cypress Diagnostics kit (Cypress Diagnostics, Belgium). G6PD genotype analysis was performed using specific primers for PCR amplification of G6PD gene containing the common African mutations A376G, G202A, A542T, and T968C. We used Chi-2 test to compare the means of qualitative data and Student’s t-test to ascertain difference between group’s characteristics. A p-value of <0.05 was deemed significant. Results: The mean value of normal G6PD activity was 16.25 U/g Hb. Enzyme activity was significantly lower in female newborns of genotype A^-(376/202) /A^-(376/202) (p<0.01) and in males genotype A^-(376/202) (p<0.001). The probability of being deficient when the test of enzymatic activity is positive among the true deficit (Se) was 0.42. The probability of being non-deficient when the test is negative among the non-deficient (Sp) was 0.89, that of being deficient when the test is positive (PPV) was 0.52 and the probability of being non-negative when the test is negative (VPN) was 0.85. Genotypes B/B, A/B, A/A, A^-(376/202)/B, A^-(376/202)/A, A^-(376/202)/A^-(376/202) were identified in female newborns with respective proportion of 39.56%, 13.19%, 7.69%, 24.18%, 13.19% and 2.20%. In males, 64.37% were genotype B, 9.20% genotype A and 26.44% genotype A^-(376/202). The northern departments had the highest frequencies of G6PD A^-(376/202) (33.18% to 37.73%) while the lowest levels were seen in the south (25.58% to 28.62%). Conclusion: Enzymatic activity showed good diagnostic value in male subjects but not in heterozygous female. The highest frequency of G6PD A^-(376/202) mutation was in the North Benin.

Keywords:
G6PD deficiency enzymatic activity DNA test neonate Benin

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Cappellini MD and Fiorelli G. Glucose-6-phosphate dehydrogenase deficiency. Lancet 2008; 371: 64-74.
[2]	Beutler E and Vulliamy TJ. Hematologically important mutations: glucose-6-phosphate dehydrogenase. Blood Cells. Mol. Dis. 2002; 28(2): 93-103.
[3]	Clark TG et al. Allelic heterogeneity of G6PD deficiency in West Africa and severe malaria susceptibility. Eur. J. Hum. Genet. 2009; 17(8): 1080-1085.
[4]	Guindo A, Fairhurst MC, Doumbo OK, Wellems TE and Diallo DA. X-Linked G6PD Deficiency Protects Hemizygous Males but Not Heterozygous Females against Severe Malaria. PLoS Med. 2007; 4: 531-532.
[5]	Carter N, Pamba A, Duparc S and Waitumbi JN. Frequency of glucose-6-phosphate dehydrogenase deficiency in malaria patients from six African countries enrolled in two randomized anti-malarial clinical trials. Malar. J. 2011; 10(1): 241-254.
[6]	WHO Working Group. Glucose-6-phosphate dehydrogenase deficiency. Bull World Health Organ 1989; 68(1): 13-24.
[7]	Vulliamy TJ et al. Polymorphic sites in the African population detected by sequence analysis of the glucose-6-phosphate dehydrogenase gene outline the evolution of the variants A and A-. Proc. Natl. Acad. Sci. 1991; 88(19): 8568‑8571.
[8]	Hirono A and Beutler E. Molecular cloning and nucleotide sequence of cDNA for human glucose-6-phosphate dehydrogenase variant A(-). Proc. Natl. Acad. Sci. 1988; 85(11): 3951-3954.
[9]	De Araujo C, Migot-Nabias F, Guitard J, Pelleau S, Vulliamy T and Ducrocq R. The role of the G6PD AEth376G/968C allele in glucose-6-phosphate dehydrogenase deficiency in the seerer population of Senegal. Haematologica 2006; 91(2): 262-263.
[10]	Amoah LE, Opong A, Ayanful-Torgby R, Abankwa J and Acquah FK. Prevalence of G6PD deficiency and Plasmodium falciparum parasites in asymptomatic school children living in southern Ghana. Malar. J. 2016; 15(1): 138-145.
[11]	Petit F, Bailly P, Chiaroni J and Mazières S. Sub-Saharan red cell antigen phenotypes and glucose-6-phosphate dehydrogenase deficiency variants in French Guiana. Malar. J. 2016; 15: 310-316.
[12]	Minucci A, Giardina B, Zuppi C and Capoluongo E. Glucose-6-phosphate dehydrogenase laboratory assay: How, when, and why? IUBMB Life 2009; 61(1): 27-34.
[13]	Disteche CM and Berletch JB. X-chromosome inactivation and escape. J. Genet. 2015; 94(4): 591-599.
[14]	Reclos GJ, Hatzidakis CJ and Schulpis KH. Glucose-6-phosphate dehydrogenase deficiency neonatal screening: preliminary evidence that a high percentage of partially deficient female neonates are missed during routine screening. J. Med. Screen. 2000; 7(1): 46-51.
[15]	Bouanga JC, Mouélé R, Préhu C, Wajcman H, Feingold J and Galactéros F. Glucose-6-Phosphate Dehydrogenase Deficiency and Homozygous Sickle Cell Disease in Congo. Hum. Hered. 1998; 48(4): 192-197.
[16]	Doupa D, Boye O, Ndiaye M, Djité M, Matar P et al. Prevalence of glucose-6-phosphate dehydrogenase (G6PD) deficiency (A-376/202) in homozygous sickle cell patients in Senegal and its clinical impact. Afr. J. Biochem. Res. 2018; 12(6): 55-62.
[17]	Vaca G and Arámbula Meraz E. DNA sequencing analysis of several G6PD variants previously defined by PCR-restriction enzyme analysis. Genet. Mol. Biol. 2016; 29(1): 31-35.
[18]	Fiogbe SEM, Akpovi DC, Segbo JGA et al. Exploring biomarkers of anemia in neonates with glucose-6-phosphate dehydrogenase deficiency. Int. J. Adv. Res. 2019; 7(8) 337-343.
[19]	Mason PJ, Bautista JM and Gilsanz F. G6PD deficiency: the genotype-phenotype association. Blood Rev. 2007; 21(5): 267-283.
[20]	Roos D, van Zwieten R, Wijnen JT, Gomez-Gallego F et al. Molecular basis and enzymatic properties of glucose 6-phosphate dehydrogenase volendam, leading to chronic nonspherocytic anemia, granulocyte dysfunction, and increased susceptibility to infections. Blood 1999; 94(9): 2955-2962.
[21]	Au WY, Ma ESK, Lam VMS, Chan JLC, Pang A and Kwong YL. Glucose 6-phosphate dehydrogenase (G6PD) deficiency in elderly Chinese women heterozygous for G6PD variants. Am. J. Med. Genet. A. 2014; 129(2): 208-211.
[22]	Sharma M, Dass J, Dhingra B and Saxena R. G6PD deficiency in females screened at tertiary care hospital. Indian J. Pathol. Microbiol. 2011; 54(4): 850-851.
[23]	Ahmed S, Saleem M, Modell B and Petrou M. Screening extended families for genetic hemoglobin disorders in Pakistan. N. Engl. J. Med. 2002; 347(15): 1162-1168.
[24]	Bittles A. Consanguinity and its relevance to clinical genetics. Clin. Genet. 2001; 60(2): 89-98.